Angle PLC ANGLE launch of Portrait Flex assay
2023年9月4日 - 3:00PM
RNSニュース (英語)
TIDMAGL
Angle PLC
04 September 2023
For immediate release 4 September 2023
ANGLE plc ("the Company")
LAUNCH OF PORTRAIT FLEX CIRCULATING TUMOR CELL ASSAY
The Portrait Flex assay provides tailored analyses performed as
a service by ANGLE's Onc-ADaPT(TM) laboratories
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company with innovative circulating tumor cell (CTC) diagnostic
solutions for the research and diagnostic oncology market, is
pleased to announce the launch of its Portrait(TM) Flex CTC assay*.
The assay is provided as a service from ANGLE's Onc-ADaPT(TM)
GCP-compliant laboratories and conducted by an expert team with
over 10 years' experience in CTC analysis.
CTCs captured and harvested using ANGLE's Parsortix(R)
technology are subsequently enumerated and characterised with the
Portrait Flex assay. Samples are analysed using immunofluorescence
staining for epithelial, mesenchymal, blood lineage and nuclear
markers, with the opportunity to include an additional biomarker
tailored to customer needs. Examples of clinically relevant CTC
biomarkers that have been researched using Parsortix technology and
published in peer-reviewed publications include HER2, PIK3CA,
PD-L1, EGFR, BRAF, AR-V7 among others.
The Portrait Flex assay has an analytical sensitivity** of
>93%, and an analytical specificity** of >95% for both
epithelial and mesenchymal markers. Data from the analysis of
clinical samples from 16 metastatic breast cancer patients
identified CTCs in 81% of patients, with 38.5% of the CTC-positive
patients having >=1 CTC with high HER2 levels highlighting the
capability to assess current HER2 status in breast cancer patients.
Of the patients with CTCs, approximately half showed a mesenchymal
only phenotype, while the others showed a mixed phenotype,
highlighting the importance of Parsortix epitope-independent
isolation of CTCs.
Combining the use of the Parsortix technology and the Portrait
Flex assay allows for testing that is specific to customer needs
and can enhance their clinical trial evaluations. ANGLE is offering
a flexible, full-service solution to help unlock precision medicine
for patients.
ANGLE Chief Commercial Officer, Brett Swansiger, commented:
"I am pleased to announce the launch of our new Portrait(TM)
Flex assay in our Onc-ADaPT(TM) clinical laboratories, the first of
a number of assays that we will be bringing to market in the coming
months for the benefit of our biopharma customers. This service,
provided by a highly experienced team, can provide valuable data
for clinical trials and contribute to the advancement in
personalized cancer care."
ANGLE Founder and Chief Executive, Andrew Newland, added:
"To support adoption of its technology by adding "content",
ANGLE has been developing a menu of imaging assays and molecular
assays to analyse the CTCs harvested by the Parsortix system. These
assays support both ANGLE's pharma services business and product
business for third-party customers."
*For Research Use Only. Not For Use in Diagnostic
Procedures.
**Analytical sensitivity = Proportions of spiked cells known to
express the marker(s) of interest which were marker positive in the
assay. Analytical specificity = Proportions of spiked cells known
to NOT express the marker(s) of interest which were marker negative
in the assay.
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Thomas Bective, Shaam Vora +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative
circulating tumor cell (CTC) diagnostic solutions for the research
and diagnostic oncology market using a simple blood sample. ANGLE's
FDA cleared and patent protected circulating tumor cell (CTC)
harvesting technology known as the Parsortix(R) system enables
complete analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular
analysis.
ANGLE's commercial businesses are focusing on diagnostic
products and clinical services. Diagnostic products include the
Parsortix(R) system and associated consumables. The clinical
services business is offered through ANGLE's GCP-compliant
laboratories in the UK and the United States. Services include
custom made assay development and clinical trial testing for
pharma.
Over 80 peer-reviewed publications have demonstrated the
performance of the Parsortix system. For more information, visit
www.angleplc.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFFFSIAAIVIIV
(END) Dow Jones Newswires
September 04, 2023 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
過去 株価チャート
から 4 2024 まで 5 2024
Angle (LSE:AGL)
過去 株価チャート
から 5 2023 まで 5 2024